<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epirubicin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epirubicin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Epirubicin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12422" href="/d/html/12422.html" rel="external">see "Epirubicin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708733"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Myocardial damage, including acute left ventricular failure, can occur with epirubicin. The risk of cardiomyopathy is proportional to the cumulative exposure, with incidence rates from 0.9% at a cumulative dose of 550 mg/m<sup>2</sup>, 1.6% at 700 mg/m<sup>2</sup>, and 3.3% at 900 mg/m<sup>2</sup>. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction before and regularly during and after treatment with epirubicin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Secondary malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Secondary acute myeloid leukemia and myelodysplastic syndrome occur at a higher incidence in patients treated with anthracyclines, including epirubicin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extravasation and tissue necrosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Extravasation of epirubicin may result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. Immediately terminate the drug and apply ice to the affected area.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F165602"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ellence</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866738"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PMS-EpiRUBicin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F165642"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anthracycline;</li>
<li>
                        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F165606"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients receiving 120 mg/m<sup>2</sup>/cycle IV as part of combination therapy (CEF-120 regimen) should receive prophylactic antibiotic therapy. Lower IV starting doses may be necessary for heavily pretreated patients, patients with preexisting myelosuppression, or with bone marrow involvement. If clinically reasonable, delay epirubicin therapy until other cardiotoxic agents with long half-lives (eg, trastuzumab) have been cleared. A lifetime maximum cumulative epirubicin dose &gt;900 mg/m<sup>2</sup> should be avoided. Actively manage modifiable cardiac risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) before initiating treatment (ASCO [Armenian 2017]). Epirubicin IV is associated with a moderate or high emetic potential (depending on regimen); antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]). Hydration and antihyperuricemic prophylaxis may minimize potential tumor lysis syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="298ca795-e965-4fc8-aad5-b5066fe046c5">Bladder cancer, non–muscle-invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, non–muscle-invasive (off-label use): Intravesical instillation: </b>50 or 80 mg as a single instillation (retained for 1 hour) within 6 hours postoperatively after transurethral resection (Berrum-Svennung 2008; Oosterlinck 1993).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37c6f975-d09e-4942-923c-df308ec4ae33">Breast cancer, adjuvant treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, adjuvant treatment:</b> Usual dose:<b> IV:</b> 100 to 120 mg/m<sup>2</sup> per 3- or 4-week treatment cycle as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">CEF-120 regimen:<b> IV: </b>60 mg/m<sup>2</sup> on days 1 and 8 every 28 days for 6 cycles in combination with cyclophosphamide and fluorouracil (Levine 2005) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">FEC-100 regimen:<b> IV: </b>100 mg/m<sup>2</sup> on day 1 every 21 days for 6 cycles in combination with cyclophosphamide and fluorouracil (Bonneterre 2005) <b>or</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f629398a-17b2-4a1a-8177-10deeef034f4">Breast cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer (off-label regimens):</b></p>
<p style="text-indent:-2em;margin-left:4em;">EC regimen: <b>IV: </b>100 mg/m<sup>2</sup> on day 1 every 21 days for 8 cycles in combination with cyclophosphamide (Piccart 2001) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">EP or EC regimen: <b>IV: </b>75 mg/m<sup>2</sup> on day 1 every 21 days for up to 6 cycles in combination with either paclitaxel or cyclophosphamide (Langley 2005) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">FEC regimen ± paclitaxel: <b>IV: </b>90 mg/m<sup>2</sup> on day 1 every 21 days for 6 cycles in combination with fluorouracil and cyclophosphamide or for 4 cycles in combination with fluorouracil and cyclophosphamide followed by paclitaxel (Martin 2008) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">FEC regimen followed by pertuzumab + trastuzumab + docetaxel: <b>IV: </b>100 mg/m<sup>2</sup> on day 1 every 21 days for 3 cycles in combination with fluorouracil and cyclophosphamide, followed by 3 cycles of pertuzumab, trastuzumab, and docetaxel (Schneeweiss 2013) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">CEF regimen: <b>IV: </b>50 mg/m<sup>2</sup> on days 1 and 8 every 21 or 28 days for 6 to 9 cycles in combination with cyclophosphamide and fluorouracil (Ackland 2001).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="982f4303-339c-4c1a-99c3-5e173bacf459">Soft tissue sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma (off-label use):</b>
<b>IV:</b> 25 mg/m<sup>2</sup> on days 1, 2, and 3 every 28 days for 4 cycles (in combination with ifosfamide and mesna) (Petrioli 2002) <b>or</b> 60 mg/m<sup>2</sup> on days 1 and 2 every 21 days for 5 cycles (in combination with ifosfamide, mesna, and filgrastim) (Frustaci 2001).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990808"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The manufacturer's labeling recommends considering lower doses (dose not specified) in patients with severe renal impairment (serum creatinine &gt;5 mg/dL). Epirubicin has not been studied in patients on dialysis.</p></div>
<div class="block doha drugH1Div" id="F50988008"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The manufacturer's labeling recommends the following adjustments (based on clinical trial information):</p>
<p style="text-indent:-2em;margin-left:2em;">Bilirubin 1.2 to 3 mg/dL or AST 2 to 4 times ULN: Administer 50% of recommended starting dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Bilirubin &gt;3 mg/dL or AST &gt;4 times ULN: Administer 25% of recommended starting dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment (Child-Pugh class C or serum bilirubin &gt;5 mg/dL): Use is contraindicated.</p></div>
<div class="block doo drugH1Div" id="F20341652"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p></div>
<div class="block dot drugH1Div" id="F51263111"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer (adjuvant therapy):</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hematologic</i>
<i>toxicity</i>: <b>Note:</b> Heavily treated patients, patients with preexisting bone marrow depression or neoplastic bone marrow infiltration: Lower starting doses (75 to 90 mg/m<sup>2</sup>) should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">Delay day 1 dose of subsequent cycles until platelets are ≥100,000/mm<sup>3</sup>, ANC ≥1,500/mm<sup>3</sup>, and nonhematologic toxicities have recovered to ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:4em;">Reduce day 1 dose in subsequent cycles to 75% of previous day 1 dose if patient experiences nadir platelet counts &lt;50,000/mm<sup>3</sup>, ANC &lt;250/mm<sup>3</sup>, neutropenic fever, or grade 3/4 nonhematologic toxicity during the previous cycle.</p>
<p style="text-indent:-2em;margin-left:4em;">For CEF-120 regimen, reduce day 8 dose to 75% of day 1 dose if platelet counts are 75,000 to 100,000/mm<sup>3</sup> and ANC is 1,000 to 1,499/mm<sup>3</sup>; omit day 8 dose if platelets are &lt;75,000/mm<sup>3</sup>, ANC &lt;1,000/mm<sup>3</sup>, or grade 3/4 nonhematologic toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Nonhematologic toxicity: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Cardiotoxicity: Discontinue epirubicin if signs/symptoms of cardiomyopathy develop. Consider discontinuation if left ventricular ejection fraction decreases or if signs/symptoms of heart failure develop. Consider dexrazoxane (if appropriate) to reduce cardiac toxicity in patients who have received a high cumulative dose of anthracycline therapy (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Asymptomatic cardiac dysfunction</i>
<i>:</i> Consider initiating heart failure medications (eg, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and/or beta blockers) in patients with asymptomatic (stage B) heart disease (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild cardiac dysfunction: </i>Continue treatment with close cardiovascular monitoring (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Moderate or severe cardiac dysfunction: </i>Interrupt treatment and utilize a multidisciplinary approach when deciding if/when to restart. Initiation of heart failure medications is recommended (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptomatic cardiac dysfunction:</i> Initiate heart failure medications (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild cardiac dysfunction: </i>Consider a multidisciplinary approach for decisions regarding treatment interruption versus continuation (ESC [Lyon 2022]). <i></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Moderate cardiac dysfunction: </i>Interrupt treatment; consider a multidisciplinary approach for decisions regarding treatment reinitiation (ESC [Lyon 2022]). <i></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe cardiac dysfunction: </i>Discontinue anthracycline therapy (ESC [Lyon 2022]).</p></div>
<div class="block doe drugH1Div" id="F165607"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Plasma clearance of epirubicin in elderly female patients was noted to be reduced by 35%. Although no initial dosage reduction is specifically recommended, particular care should be exercised in monitoring toxicity and adjusting subsequent dosage in elderly patients (particularly females &gt;70 years of age).</p></div>
<div class="block adr drugH1Div" id="F165573"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not always defined. Percentages reported as part of combination chemotherapy regimens.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Decreased left ventricular ejection fraction (asymptomatic; delayed: 1% to 2%), cardiac failure (≤2%), atrioventricular block, bradycardia, bundle branch block, cardiac arrhythmia, cardiomyopathy, ECG abnormality, myocarditis, non-specific T wave on ECG, sinus tachycardia, ST segment changes on ECG, tachyarrhythmia, thromboembolism, ventricular premature contractions, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Lethargy (1% to 46%)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Alopecia (70% to 96%), skin rash (1% to 9%), skin changes (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Amenorrhea (69% to 72%), hot flash (5% to 39%)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea and vomiting (83% to 92%; grades 3/4: 22% to 25%), mucositis (9% to 59%; grades 3/4: ≤9%), diarrhea (7% to 25%), anorexia (2% to 3%), abdominal pain, esophagitis, neutropenic enterocolitis, stomatitis, toxic megacolon</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Menopause (premature or early)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Neutropenia (54% to 80%; grades 3/4: 11% to 67%; nadir: 10 to 14 days; recovery: by day 21), leukopenia (50% to 80%; grades 3/4: 2% to 59%), anemia (13% to 72%; grades 3/4: ≤6%), thrombocytopenia (5% to 49%; grades 3/4: ≤5%), febrile neutropenia (grades 3/4: ≤6%), acute lymphocytic leukemia, acute myelocytic leukemia, myelodysplastic syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Ascites, hepatomegaly, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Infection (15% to 22%; grades 3/4: ≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction (3% to 20%; grades 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Conjunctivitis (1% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea, pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, case reports: Anaphylaxis, arterial embolism, burning sensation of gastrointestinal tract, chills, dehydration, erythema, flushing, gastrointestinal erosion, gastrointestinal hemorrhage, gastrointestinal pain, gastrointestinal ulcer, hyperuricemia, nail hyperpigmentation, oral mucosa hyperpigmentation, phlebitis, pneumonia, pulmonary embolism, radiation recall phenomenon, red urine discoloration, sepsis, shock, skin hyperpigmentation, skin photosensitivity, thrombophlebitis, urticaria</p></div>
<div class="block coi drugH1Div" id="F165587"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe hypersensitivity to epirubicin, other anthracyclines, anthracenediones, or any component of the formulation; severe myocardial insufficiency, recent myocardial infarction, or severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose; severe persistent drug-induced myelosuppression; severe hepatic impairment (Child-Pugh class C or serum bilirubin &gt;5 mg/dL).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Marked persistent myelosuppression induced by prior treatment with other chemotherapy agents or by radiotherapy.</p></div>
<div class="block war drugH1Div" id="F165570"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur. Leukopenia, neutropenia, thrombocytopenia, and anemia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac toxicity: Myocardial damage, including acute left ventricular failure, can occur with epirubicin. The risk of cardiomyopathy is proportional to the cumulative exposure, with incidence rates from 0.9% at a cumulative dose of 550 mg/m<sup>2</sup>, 1.6% at 700 mg/m<sup>2</sup>, and 3.3% at 900 mg/m<sup>2</sup>. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Early toxicity may consist of sinus tachycardia and/or ECG changes, such as nonspecific ST-T wave changes. Tachycardia, including premature ventricular contractions and ventricular tachycardia, as well as bradycardia, have occurred. Atrioventricular and bundle-branch block have also been reported. These early cardiotoxicities are not necessarily predictive of subsequent delayed cardiotoxicity and are not necessarily a reason to suspend epirubicin therapy. Delayed cardiotoxicity is typically caused by cardiomyopathy, which presents as decreased left ventricular ejection fraction (LVEF) and/or signs/symptoms of heart failure. Delayed cardiotoxicity typically develops late during epirubicin therapy, or within 2 to 3 months after completion of epirubicin; cardiotoxicity has been reported several months to years after therapy termination. The recommended lifetime epirubicin cumulative dose is 900 mg/m<sup>2</sup>; avoid cumulative doses above this. Total cumulative dose should take into account prior treatment with other anthracyclines or anthracenediones, previous or concomitant treatment with other cardiotoxic agents, or irradiation of chest. Although the risk increases with cumulative dose, irreversible cardiotoxicity may occur at any dose level. Active or dormant cardiovascular disease, concurrent or recent administration of cardiotoxic drugs, prior therapy with other anthracyclines or anthracenediones, or prior or concurrent chest (mediastinal/pericardial area) irradiation may increase the risk of developing late cardiac toxicity. Children may be at increased risk for developing acute and/or delayed cardiotoxicity. The half-life of other cardiotoxic agents (eg, trastuzumab) must be considered in sequential therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">According to ASCO guidelines (ASCO [Armenian 2017]), the risk of cardiac dysfunction is increased with high-dose anthracycline therapy (eg, equivalent to doxorubicin ≥250 mg/m<sup>2</sup>); high-dose radiotherapy (≥30 Gy) with the heart in the treatment field; lower-dose anthracyclines (eg, equivalent to doxorubicin &lt;250 mg/m<sup>2</sup>) in combination with lower-dose radiotherapy (&lt;30 Gy) with the heart in the treatment field; lower-dose anthracyclines AND any of the following risk factors: ≥2 cardiovascular risk factors (including smoking, hypertension, diabetes, dyslipidemia, and obesity) during or after completion of therapy or ≥60 years of age at cancer treatment, or compromised cardiac function (eg, borderline low LVEF [50% to 55%], history of MI, moderate or higher valvular heart disease) before or during treatment; treatment with lower-dose anthracycline followed by trastuzumab (sequential therapy); other risk factors for anthracycline-induced cardiotoxicity include age ≥60 years at time of treatment and 2 or more cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidemia, or obesity) during or after treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Extravasation of epirubicin may result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. If extravasation occurs, immediately terminate administration and apply ice to the affected area. Local tissue injury may manifest as blistering, ulceration, or necrosis. Consider extravasation if burning/stinging occurs during infusion, or if other signs indicating perivenous infiltration or extravasation are present; extravasation may occur even when blood return is present on aspiration, or in patients without burning/stinging symptoms. Injection into a small vein or repeated administration in the same vein may result in venous sclerosis. Avoid veins over joints or in extremities with compromised venous or lymphatic drainage. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. If perivenous infiltration occurs, immediately discontinue infusion and restart in another vein. If appropriate, dexrazoxane may be considered (if within 6 hours of extravasation).</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Secondary acute myelogenous leukemia and myelodysplastic syndrome occur at a higher incidence in patients treated with anthracyclines, including epirubicin. The latency period for secondary leukemias may be short (1 to 3 years).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Thrombophlebitis and thromboembolic phenomena (including pulmonary embolism) have occurred; some cases have been fatal. Local phlebitis or thrombophlebitis may be preceded by facial flushing and erythematous streaking along the vein (may be indicative of excessively rapid administration).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Epirubicin may cause tumor lysis syndrome (TLS), particularly in patients with rapid tumor proliferation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older age: Females ≥70 years of age should be closely monitored for toxicity due to the possibility of decreased epirubicin clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children may be at increased risk for developing acute and delayed cardiotoxicity; long-term periodic cardiac function monitoring is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation recipients: Epirubicin may increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver. Radiation recall, including cutaneous and pulmonary toxicity, may occur in patients who receive epirubicin after prior radiation therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should not be immunized with live or live-attenuated viral vaccines during or shortly after treatment; serious or fatal infection may result in immunocompromised patients. Inactivated vaccines may be administered; however, response may be diminished.</p></div>
<div class="block foc drugH1Div" id="F165581"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ellence: 50 mg/25 mL (25 mL); 200 mg/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/25 mL (25 mL [DSC]); 200 mg/100 mL (100 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F165566"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323129"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ellence Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/25 mL (per mL): $2.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/100 mL (per mL): $2.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866739"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (5 mL, 25 mL, 100 mL)</p></div>
<div class="block adm drugH1Div" id="F165584"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Epirubicin is associated with a moderate or high emetic potential (depending on regimen); antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>IV:</b> Infuse over 15 to 20 minutes or slow IV push; if lower doses due to dose reduction are administered, may reduce infusion time proportionally. Do not infuse over &lt;3 minutes. Infuse into a free-flowing IV solution (NS or D<sub>5</sub>W). Avoid the use of veins over joints or in extremities with compromised venous or lymphatic drainage.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (ESMO/EONS [Pérez Fidalgo 2012]); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dexrazoxane:</i> 1,000 mg/m<sup>2</sup> (maximum dose: 2,000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m<sup>2</sup> (maximum dose: 1,000 mg) IV over 1 to 2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (± 3 hours) as the dose on day 1 (Mouridsen 2007; ESMO/EONS [Pérez Fidalgo 2012]). <b>Note:</b> Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl &lt;40 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DMSO:</i> Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (ESMO/EONS [Pérez Fidalgo 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Intravesicular administration (off-label use):</b> Instill into bladder and retain for 1 hour (Berrum-Svennung 2008; Oosterlinck 1993).</p></div>
<div class="block hazard drugH1Div" id="F49132442"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F165582"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Breast cancer, adjuvant treatment:</b> Adjuvant therapy component for primary breast cancer in patients with evidence of axillary node tumor involvement.</p></div>
<div class="block off-label drugH1Div" id="F25725540"><span class="drugH1">Use: Off-Label: Adult</span><p>Bladder cancer, non–muscle-invasive; Soft tissue sarcoma</p></div>
<div class="block mst drugH1Div" id="F165651"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">EpiRUBicin may be confused with DAUNOrubicin, DOXOrubicin, eriBULin, IDArubicin, valrubicin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ellence [US] may be confused with Elase brand name for dornase alfa [Chile, France, Malaysia]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This drug is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299273"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F165575"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine.  Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bevacizumab: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of EpiRUBicin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fam-Trastuzumab Deruxtecan: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with fam-trastuzumab deruxtecan should avoid anthracycline-based therapy for up to 7 months after stopping fam-trastuzumab deruxtecan. Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Margetuximab: Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased.  Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taxane Derivatives: May enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trastuzumab: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab.  Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49185426"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should be advised to use effective contraception and avoid becoming pregnant during treatment. Patients with partners who could become pregnant should use effective contraception during and after treatment. Epirubicin may cause irreversible amenorrhea.</p></div>
<div class="block pri drugH1Div" id="F165589"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in animal reproduction studies. Pregnant caregivers should avoid handling epirubicin.</p>
<p style="text-indent:0em;margin-top:2em;">Limited information is available from a retrospective study of patients who received epirubicin (in combination with cyclophosphamide or weekly as a single-agent) during the second or third (prior to week 35) trimester for the treatment of pregnancy-associated breast cancer (Ring 2005) and from a study of women who received epirubicin (weekly as a single-agent) at gestational weeks 16 through 30 for the treatment of pregnancy-associated breast cancer (Peccatori 2009). Some pharmacokinetic properties of epirubicin may be altered in pregnant women (van Hasselt 2014). The European Society for Medical Oncology (ESMO) has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy (ESMO [Peccatori 2013]); the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). If chemotherapy is indicated, it should not be administered in the first trimester, but may begin in the second trimester. There should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation.</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F165590"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if epirubicin is present in human breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for ≥7 days after the last epirubicin dose.</p></div>
<div class="block mop drugH1Div" id="F165579"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor cumulative (lifetime) anthracycline/epirubicin dose. Baseline and repeated measurements of CBC with differential, LFTs (total bilirubin, ALT, AST), serum creatinine. If at risk for tumor lysis syndrome, monitor serum uric acid, potassium, calcium, phosphate, and serum creatinine after initial dose. Assess left ventricular ejection fraction (LVEF) before and regularly during and after epirubicin treatment. The method used for assessment of LVEF (ECG or MUGA) should be consistent during routine monitoring. Obtain ECG. Evaluate pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor injection site during infusion for possible extravasation or local reactions. Monitor for signs/symptoms of tumor lysis syndrome. Monitor for secondary malignancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional cardiovascular monitoring (ASCO [Armenian 2017], ESC [Lyon 2022]):</i> Comprehensive assessment prior to treatment, including a history and physical examination and screening for cardiovascular disease risk factors, such as hypertension, diabetes, dyslipidemia, obesity, and smoking; echocardiogram (transthoracic preferred, perform at baseline and 12 months after therapy completion for all patients; in addition, perform every 2 cycles and within 3 months after therapy completion for high- or very high-risk patients). Cardiac biomarkers (troponin and natriuretic peptide at baseline for high and very high-risk patients [may consider for low- and moderate-risk]; also prior to each cycle during anthracycline treatment and at 3 and 12 months after therapy completion for high- and very high-risk patients). In patients who develop signs/symptoms of cardiac dysfunction during therapy, an echocardiogram is recommended for diagnostic workup; if echocardiogram is not available or feasible, a cardiac MRI (preferred) or multigated acquisition (MUGA) scan may be utilized; obtain serum cardiac biomarkers. Refer to a cardiologist when clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F165569"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Epirubicin is an anthracycline antineoplastic agent; known to inhibit DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs; active throughout entire cell cycle. Intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Also inhibits DNA helicase, and generates cytotoxic free radicals.</p></div>
<div class="block phk drugH1Div" id="F165586"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>dss</sub>: 21 to 27 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~77% to albumin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively via hepatic and extrahepatic (including RBCs) routes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Triphasic; Mean terminal: 33 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (34% to 35%); urine (20% to 27%)</p></div>
<div class="block phksp drugH1Div" id="F51154044"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance was reduced by 50% in patients with serum creatinine ≥5 mg/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance was reduced by ~30% in patients with elevated AST levels and normal bilirubin, and by ~50% in patients with elevated AST and bilirubin levels, as compared to patients with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma clearance of epirubicin in elderly female patients was reduced by 35% as compared to younger female patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F165591"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin ebewe</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">E.P.R Elvetium | Epirubicina microsules</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Epi Cell | Epirubicin accord | Epirubicin actavis | Epirubicin arcana | Epirubicin ebewe | Epirubicin Hikma | Epirubicinhydrochlorid Hospira | Farmorubicin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">DBL Epirubicin | Epiccord | Epirube | Epirubicin | Epirubicin actavis | Epirubicin kabi | Epirubicin sz | Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin actavis | Epirubicin Hospira | Epirubicine accord healthcare | Epirubicine hcl sandoz | Epirubicine Mylan | Epirubicine Teva | Farmorubicine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Epilem | Tevarubicin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Brecila | Cloridrato de epirrubicina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin actavis | Epirubicin cancernova | Epirubicin ebewe | Epirubicin Mepha | Epirubicin Sandoz | Epirubicin sandoz eco | Epirubicin teva | Farmorubicin | Farmorubicin rd</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai da sheng</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Epirubicina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Epimedac | Epirubicin | Epirubicin accord | Epirubicin actavis | Epirubicin teva | Farmorubicin cs | Farmorubicin pfs</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Axirubicin e | Bendaepi | Bw Picin | Epi | Epi Nc | Epi onkovis | Epi Teva | Epimedac | Epirubicin | Epirubicin actavis | Epirubicin amneal | Epirubicin aurobindo | Epirubicin axios | Epirubicin HCL | Epirubicin hcl phares | Epirubicin Hexal | Epirubicin kabi | Epirubicin Medicop | Epirubicin Omnicare | Epirubicin Oncotrade | Epirubicin onkovis | Epirubicin Profusio | Epirubicin Roth | Epirubicin Temmler | Epirubicin vipharm | Epirubicin vitane | Epirubicin zyo | Eracin | Eurorubicin | Farmorubicin | Farmorubicin cs | Farmorubicin hl | Farmorubicina | Farmorubicine | Riboepi</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Farmorubicina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin accord | Epirubicin actavis | Epirubicin ebewe | Epirubicin teva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Epirubicin ebewe | Epirubicine Mylan | Farmorubicin | Pharmorubicin | Riboepi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Epimedac | Epirubicina accord | Epirubicina actavis | Epirubicina teva | Farmorubicina | Sendras</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin accord | Epirubicin actavis | Epirubicin ebewe | Epirubicin Hospira | Epirubicin Mayne | Epirubicin medac | Epirubicin Mylan | Epirubicin sanoswiss | Epirubicin teva | Farmorubicin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Epirubicine Accord | Epirubicine actavis | Epirubicine arrow | Epirubicine Intsel chimos | Epirubicine kabi | Epirubicine Medac | Farmorubicine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Pharmorubicin | Trav epirubicin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Epibicin | Epibra | Epimedac | Epirrubicina aurovitas | Epirub | Epirubicin generics | Epirubicin Hydrochloride Pharmachemie | Epirubicin/generics | Farmorubicin | Megarubicin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Episindan | Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin ebewe</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Epirubicin kabi | Epirubicin teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ciazil | Epirubicin | Kemopirin | Rubisandin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adricin | Ciprubicin | Epirubicin | Episar | Farmorubicin | Lilbecep | Stribicin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Epirubicina | Epirubicina accord | Epirubicina kabi | Epirubicina teva | Farmorubicina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin hydrochloride Sandoz | Farmorubicin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adricin | Anthracin | Epicord | Epintas</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Boryung epirubicin hcl | Donga epirubicin | Epirubicin | Ildong pharmorubicin pfs | Pfizer epirubicine | Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin ebewe</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin ebewe | Epirubicine Mylan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin accord | Epirubicin ebewe</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Epirubicin accord | Epirubicin actavis</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Epilem | Epiplasical | Ibic</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anthracin | E.P. Mycin | Epicn | Epirubicin | Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin aqvida | Epirubicin HCL | Pharmorubicin cs</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Epirubicine HCl CF | Epirubicine HCl Ebewe | Epirubicine HCl Hikma | Epirubicine hcl PCH | Epirubicinehydrochloride accord | Epirubicinehydrochloride Fresenius Kabi | Farmorubicine r.t.u. | Farmorubicine rtu</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin accord | Epirubicin medac | Epirubicin teva | Farmorubicin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin ebewe | Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Epirubicina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anthracin | E.P. Mycin | Epivid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin ebewe | Rubisol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Epimedac | Epirubicin accord | Epirubicin actavis | Epirubicin cancernova | Epirubicin ebewe | Epirubicine actavis | Episindan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ellence | Epirubicin | Epirubicin HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Epi Cell | Epirrubicina | Epirrubicina accord | Epirrubicina Medac | Epirrubicina sandoz | Epirrubicina Teva | Farmorubicina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Epirubicina fusa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Farmorubicin RD</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ecclepia | Epirubicina actavis | Epirubicina kabi | Epirubicina teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Epirubicin ebewe | Epirubicin vero</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Epirubicin HCL | Epirubicin jazeera</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin accord | Epirubicin actavis | Epirubicin ebewe | Epirubicin teva | Farmorubicin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin hydrochloride hospira | Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Epirubicin | Epirubicinijev klorid pch | Episindan | Farmorubicin pfs</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Epimedac | Epirubicin | Epirubicin accord | Epirubicin actavis | Epirubicin Hikma | Epirubicin Mylan | Farmorubicin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anthracin | Epirubicin ebewe | Farmorubicin | Pharmorubicin cs</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cytobicine | Epirubicine Ebewe | Farmorubicine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Epiritu | Epirubicin ebewe | Epirubicin kocak | Pirucin | Rubens</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anthracin | Epicin | Epirubicin | Epirudo | Pharmorubicin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Epilik | Epirubicin | Epirubicin amaxa | Epirubicin ebewe</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Epirubicin | Epicord | Epirubicin Hexal | Farmorubicin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11181656">
<a name="11181656"></a>Ackland SP, Anton A, Breitbach GP, et al. Dose-Intensive Epirubicin-Based Chemotherapy is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study. <i>J Clin Oncol</i>. 2001;19(4):943-953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/11181656/pubmed" id="11181656" target="_blank">11181656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17997459">
<a name="17997459"></a>Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. <i>J Urol</i>. 2008;179(1):101-105;discussion 105-106. doi:10.1016/j.juro.2007.08.166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/17997459/pubmed" id="17997459" target="_blank">17997459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837983">
<a name="15837983"></a>Bonneterre J, Roché H, Kerbrat P, et al. Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial. <i>J Clin Oncol</i>. 2005;23(12):2686-2693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/15837983/pubmed" id="15837983" target="_blank">15837983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19901117">
<a name="19901117"></a>Burnell M, Levine MN, Chapman JA, et al. Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. <i>J Clin Oncol</i>. 2010;28(1):77-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/19901117/pubmed" id="19901117" target="_blank">19901117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27317986">
<a name="27317986"></a>Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. <i>J Urol</i>. 2016;196(4):1021-1029. doi:10.1016/j.juro.2016.06.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/27317986/pubmed" id="27317986" target="_blank">27317986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19879750">
<a name="19879750"></a>Eiermann W, Graf E, Ataseven B, et al. Dose-Intensified Epirubicin Versus Standard-Dose Epirubicin/Cyclophosphamide Followed by CMF in Breast Cancer Patients With 10 or More Positive Lymph Nodes: Results of a Randomised Trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group. <i>Eur J Cancer</i>. 2010;46(1):84-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/19879750/pubmed" id="19879750" target="_blank">19879750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ellence.1">
<a name="Ellence.1"></a>Ellence (epirubicin hydrochloride) [prescribing information]. New York, NY: Pfizer; May 2023.</div>
</li>
<li>
<div class="reference">
                  Epirubicin hydrochloride injection [prescribing information]. Lake Forest, IL: Hospira Inc; November 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of Cancer Therapy. <i>J Clin Oncol</i>. 2005;23(30):7685-7696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11230464">
<a name="11230464"></a>Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. <i>J Clin Oncol</i>. 2001;19(5):1238-1247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/11230464/pubmed" id="11230464" target="_blank">11230464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16293863">
<a name="16293863"></a>Langley RE, Carmichael J, Jones AL, et al. Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01. <i>J Clin Oncol</i>. 2005;23(33):8322-8330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/16293863/pubmed" id="16293863" target="_blank">16293863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16051958">
<a name="16051958"></a>Levine MN, Pritchard KI, Bramwell VH, et al. Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. <i>J Clin Oncol</i>. 2005;23(22):5166-5170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/16051958/pubmed" id="16051958" target="_blank">16051958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18505968">
<a name="18505968"></a>Martin M, Rodríguez-Lescure A, Ruiz A, et al. Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>J Natl Cancer Inst</i>. 2008;100(11):805-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/18505968/pubmed" id="18505968" target="_blank">18505968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17185744">
<a name="17185744"></a>Mouridsen HT, Langer SW, Buter J, et al. Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies. <i>Ann Oncol</i>. 2007;18(3):546-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/17185744/pubmed" id="17185744" target="_blank">17185744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8455236">
<a name="8455236"></a>Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. <i>J Urol</i>. 1993;149(4):749-752. doi:10.1016/s0022-5347(17)36198-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/8455236/pubmed" id="8455236" target="_blank">8455236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18712595">
<a name="18712595"></a>Peccatori FA, Azim HA Jr, Scarfone G, et al. Weekly Epirubicin in the Treatment of Gestational Breast Cancer (GBC). <i>Breast Cancer Res Treat</i>. 2009;115(3):591-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/18712595/pubmed" id="18712595" target="_blank">18712595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12393986">
<a name="12393986"></a>Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. <i>Am J Clin Oncol</i>. 2002;25(5):468-473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/12393986/pubmed" id="12393986" target="_blank">12393986</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pharmorubicin PFS (epirubicin hydrochloride) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11408507">
<a name="11408507"></a>Piccart MJ, Di Leo A, Beauduin M, et al. Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer. <i>J Clin Oncol.</i> 2001;19(12):3103-3110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/11408507/pubmed" id="11408507" target="_blank">11408507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15961766">
<a name="15961766"></a>Ring AE, Smith IE, Jones A, et al. Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals. <i>J Clin Oncol</i>. 2005;23(18):4192-4197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/15961766/pubmed" id="15961766" target="_blank">15961766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):S119-S133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23704196">
<a name="23704196"></a>Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). <i>Ann Oncol</i>. 2013;24(9):2278-2284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/23704196/pubmed" id="23704196" target="_blank">23704196</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713311">
<a name="24713311"></a>van Hasselt JG, van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. <i>Ann Oncol</i>. 2014;25(10)2059-2065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epirubicin-drug-information/abstract-text/24713311/pubmed" id="24713311" target="_blank">24713311</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8663 Version 357.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
